Abstract 164P
Background
Immune checkpoint inhibitors (ICI) were demonstrated to extend survival in patients with metastatic esophageal squamous cell carcinoma (ESCC). However, the role of ICI in locally advanced ESCC is not yet established. Herein, we conducted a retrospective study to evaluate the efficacy and safety of ICI plus neoadjuvant concurrent chemoradiotherapy (CCRT) for patients with locally advanced ESCC.
Methods
ESCC patients treated with neoadjuvant CCRT were retrospectively recruited into our study. Patients were classified into ICI-CCRT and CCRT according to regimens during CCRT. ICI-CCRT referred to ICI plus chemoradiotherapy while CCRT referred to chemoradiotherapy alone. Kaplan-Meier curves were estimated for recurrent-free survival (RFS) and overall survival (OS).
Results
A total of 150 patients were enrolled into our study, with 43 patients in ICI-CCRT and 107 patients in CCRT group. The median age was 58.5 years old of our patients and median follow-up period were 22 months. As for patients in ICI-CCRT, 33 patients received nivolumab plus CCRT and 10 patients received pembrolizumab plus CCRT. The median RFS was not reach (NR) versus 16.2 months in ICI-CCRT and CCRT group, respectively (p= 0.016). The median OS was not reach (NR) versus 20.0 months in ICI-CCRT and CCRT group, respectively (p= 0.002). The response rates were significantly higher in IC-CCRT, accounting for 74 % versus 65 % in ICI-CCRT arm and CCRT arm, respectively. Multivariate analysis showed ICI-CCRT was an independent predictor associated with survival. Grade 3/4 adverse events were comparable between each group.
Conclusions
Neoadjuvant ICI-CCRT is superior to CCRT for locally advanced ESCC patients with similar toxicity profiles. Further prospective studies are warranted to validate our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract